Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.57 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.57 |
| ▸ | NPY4R | P50391 | 6/20 | 0.53 |
| ▸ | NPY1R | P25929 | 5/20 | 0.53 |
| ▸ | NPY2R | P49146 | 2/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 1/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934595 | 0.91 | NMUR2 (0.58) | NMUR2NMUR1RAMP3CALCRNTSR1 | |
| SCHEMBL31187483 | 0.86 | NMUR2 (0.63) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL30895016 | 0.86 | RAMP3 (0.64) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL30792437 | 0.86 | NMUR2 (0.56) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL30678863 | 0.86 | NMUR2 (0.56) | NMUR2NMUR1 | |
| SCHEMBL31473044 | 0.85 | NMUR2 (0.58) | NMUR2NMUR1MAPK8MAPK9MAPK10 | |
| SCHEMBL30695569 | 0.85 | OPRM1 (0.56) | NMUR2NMUR1NTSR2NTSR1 | |
| SCHEMBL32681766 | 0.85 | APLNR (0.59) | NPY4RNPY1RNPY2RNPY5RCALCR | |
| SCHEMBL16566024 | 0.85 | RAMP3 (0.62) | NPY4RNPY1RNPY2RNPY5RRAMP3 | |
| SCHEMBL31679344 | 0.84 | NTSR1 (0.60) | NMUR2NMUR1NPY1RNTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12048732-B2 | Methods of treating breast cancer | Blaze Bioscience, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. | 2023-08-17 | — | — | US | disclosed |
| US-20230037660-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. | 2023-02-09 | — | — | US | disclosed |
| EP-4076500-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | CHLSN, SLC47A1, CLSPN | NMUR2 1904/4885NMUR1 1551/4885NPY4R 2341/4885 |
| US-20230037660-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | FLT4, FLT1, KDR | NMUR2 903/4885NMUR1 705/4885NPY4R 938/4885 |
| US-12048732-B2 | Methods of treating breast cancer | BRCA1, HUNK, MLEC | NMUR2 1088/4885NMUR1 719/4885NPY4R 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.